TRIM27 protein expression inhibitor and application thereof in preparation of medicine for treating non-small cell lung cancer and regulation and control of stability and / or expression level of TP53 protein

By developing TRIM27 protein expression inhibitors, knocking down TRIM27 and regulating TP53 protein, the survival, migration, invasion and dryness of NSCLC cells was solved, providing a more effective therapeutic strategy and enhancing the therapeutic effect of NSCLC.

CN118995814APending Publication Date: 2024-11-22JIAXING NO 1 HOSPITAL
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202411076253.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-07
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

The prior art is difficult to effectively identify and target biomarkers and drug targets in non-small cell lung cancer (NSCLC), and some NSCLC patients are resistant to EGFR tyrosine kinase inhibitors. High expression of TRIM27 in tumor cells promotes cancer progression , but its regulatory mechanism is not fully understood.

Method used

Develop TRIM27 protein expression inhibitors, and use shRNA plasmid to reduce the survival, migration, invasion and dryness of NSCLC cells, and regulate the stability and expression level of TP53 protein, enhance the stability and expression of TP53, thereby inhibiting NSCLC. Proliferation and dryness of cells.

Benefits of technology

By reducing TRIM27 expression, the viability, migration, invasion and dryness of NSCLC cells are significantly reduced, the ubiquitination level of TP53 is weakened, the stability and expression of TP53 protein is enhanced, and the proliferation and dryness of NSCLC cells are inhibited, providing a more effective treatment strategies.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118995814A_ABST
    Figure CN118995814A_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of biological medicine. The invention provides a TRIM27 protein expression inhibitor and application thereof in preparation of drugs for treating non-small cell lung cancer and regulation and control of TP53 protein stability and / or expression level. Knock-down of TRIM27 can reduce survival, migration, invasion and dryness of NSCLC cells. Meanwhile, the expression of TP53 can be enhanced by knocking down TRIM27, and the protein level of TP53 is improved, so that the proliferation and dryness of non-small cell lung cancer cells are inhibited; and the ubiquitination level of TP53 can be weakened, and the stability of TP53 protein is enhanced. The method is of great significance to more effective identification of biomarkers and drug targets and NSCLC treatment.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biomedicine technology, and in particular to a TRIM27 protein expression inhibitor and its application in preparing a drug for treating non-small cell lung cancer and regulating the stability and / or expression level of TP53 protein. Background Art

[0002] Over the past few decades, the number of deaths caused by lung cancer has been declining due to the advancement of treatment strategies. Despite this, 27% of cancer-related deaths still come from lung cancer. Lung cancer can be divided into non-small cell lung carcinoma (NSCLC) and small cell lung cancer based on pathological characteristics. Non-small cell lung cancer is the most common subtype of lung cancer, which determines the overall treatment outcome of lung cancer. NSCLC patients can be further divided into two major subtypes: lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC). Biomarkers that predict the diagnosis and prognosis of patients with non-small cell lung cancer play an important role in clinical guidance in improving the 5-year survival rate of patients. Most NSCLC patients have epidermal growth factor receptor (EGFR) mutations, which may lead to a malignant phenotype. Inhibiting EGFR mutations can help treat NSCLC patients. These findings suggest that exploring the molecular mechanisms of the development of non-small cell lung cancer can help develop new treatment strategies. However, some NSCLC patients are resistant to tyrosine kinase inhibitors that inhibit EGFR. Therefore, more effective identification of biomarkers and drug targets is of great significance for the treatment of NSCLC.

[0003] Ubiquitination is a key process that controls protein fate at the post-translational level. One of the major consequences of polyubiquitination is that target proteins are degraded by proteasomes or lysosomes. In addition to E1 ubiquitin-activating enzymes and E2 ubiquitin-conjugating enzymes, E3 ligases are responsible for selecting and interacting with downstream target proteins, which are then tagged with ubiquitin. K48-polyubiquitinated proteins are subsequently destabilized by proteasome- or lysosome-mediated degradation. Ubiquitin E3 ligase TRIM27 is a fusion partner of the proto-oncogene tyrosine-protein kinase receptor Ret and is highly expressed in a variety of tumor cells and tissues. In addition, TRIM27 can promote the progression of a variety of cancers, including esophageal and colorectal cancers. In esophageal cancer cells, TRIM27 increases cell survival by promoting polyubiquitination and degradation of PTEN. Although studies have shown that TRIM27 promotes the occurrence and metastasis of NSCLC through the ubiquitination and degradation of SIX3, the mechanism by which TRIM27 regulates the occurrence and development of NSCLC remains to be further studied. Summary of the invention

[0004] The purpose of the present invention is to provide a TRIM27 protein expression inhibitor and its use in preparing drugs for treating non-small cell lung cancer and regulating the stability and / or expression level of TP53 protein. By knocking down TRIM27, the survival, migration, invasion and stemness of NSCLC cells can be reduced, and the ubiquitination level of TP53 can be weakened, the stability and expression level of TP53 protein can be enhanced, and then the proliferation and stemness of non-small cell lung cancer cells can be inhibited, which is of great significance for more effectively identifying biomarkers and drug targets for the treatment of NSCLC.

[0005] In order to achieve the above-mentioned object of the invention, the present invention provides the following technical solutions:

[0006] The present invention provides a TRIM27 protein expression inhibitor, including a shRNA plasmid for knocking down TRIM27.

[0007] Preferably, the functional sequences in the shRNA plasmid include the shTRIM27-1 sequence group, the shTRIM27-2 sequence group and the shTRIM27-3 sequence group.

[0008] Preferably, the shTRIM27-1 sequence group includes shTRIM27-1-F and shTRIM27-1-R, the sequence of shTRIM27-1-F is shown in SEQ ID NO.1, and the sequence of shTRIM27-1-R is shown in SEQ ID NO.2.

[0009] Preferably, the shTRIM27-2 sequence group includes shTRIM27-2-F and shTRIM27-2-R, the sequence of shTRIM27-2-F is shown in SEQ ID NO.3, and the sequence of shTRIM27-2-R is shown in SEQ ID NO.4.

[0010] Preferably, the shTRIM27-3 sequence group includes shTRIM27-3-F and shTRIM27-3-R, the sequence of shTRIM27-3-F is shown in SEQ ID NO.5, and the sequence of shTRIM27-3-R is shown in SEQ ID NO.6.

[0011] The present invention provides the use of the TRIM27 protein expression inhibitor in preparing a drug for treating non-small cell lung cancer.

[0012] The present invention provides the use of the TRIM27 protein expression inhibitor in preparing a drug for reducing the vitality of non-small cell lung cancer cells.

[0013] The present invention provides the use of the TRIM27 protein expression inhibitor in the preparation of a drug for reducing the migration and invasion ability of non-small cell lung cancer cells.

[0014] The present invention provides the use of the TRIM27 protein expression inhibitor in preparing a drug for reducing the stemness of non-small cell lung cancer cells.

[0015] The present invention also provides the use of TRIM27 protein in the preparation of a drug for regulating the stability of TP53 protein. Inhibiting the expression of TRIM27 protein can promote the maintenance of the stability of TP53 protein.

[0016] The present invention also provides the use of TRIM27 protein in preparing a reagent for regulating the expression level of TP53 protein. In cells, inhibiting the expression of TRIM27 protein can increase the expression level of TP53 protein.

[0017] The present invention also provides a regulator for regulating TP53 protein stability and / or TP53 protein expression level, including the TRIM27 protein expression inhibitor.

[0018] By adopting the above technical solution, the present invention has the following beneficial effects:

[0019] The technical solution of the present invention provides a TRIM27 protein expression inhibitor, which can knock down TRIM27, has the effect of reducing the viability, migration, invasion and stemness of NSCLC cells, and can be used to treat non-small cell lung cancer. Moreover, there is an interaction between TP53 and TRIM27, and the reduction of TRIM27 will enhance the expression of TP53; when TRIM27 is knocked down, the ubiquitination level of TP53 is weakened; the ectopic expression of TRIM27 destroys the stability of TP53 protein. In addition, knocking down TRIM27 can increase the level of TP53 protein, thereby inhibiting the proliferation and stemness of non-small cell lung cancer cells. This is of great significance for more effective identification of biomarkers and drug targets for the treatment of NSCLC. BRIEF DESCRIPTION OF THE DRAWINGS

[0020] Figure 1 is a comparison of TRIM27 mRNA expression levels in normal and tumor tissues;

[0021] Figure 2 The differential expression of TRIM27 mRNA in normal tissue samples and primary tumor samples of LUAD or LUSC patients in the UALCAN database ( Figure 2 A is LUAD, B is LUSC);

[0022] Figure 3 The differential expression of TRIM27 mRNA in normal tissue samples and tumor samples of LUAD or LUSC patients in the TNMplot database ( Figure 3 A is LUAD, B is LUSC);

[0023] Figure 4 TRIM27 mRNA expression analysis in different indication subtypes of LUAD patients ( Figure 4 A is the invasive grade, B is the lymph node metastasis status, C is the TP53 mutation status, D is the patient's age, E is the race, and F is the gender);

[0024] Figure 5 TRIM27 mRNA expression analysis in different indicated subtypes of LUSC patients ( Figure 5 A is the invasive grade, B is the lymph node metastasis status, C is the TP53 mutation status, D is the patient's age, E is the race, and F is the gender);

[0025] Figure 6 The relationship between TRIM27 mRNA expression level and overall survival (OS) of NSCLC patients ( Figure 6 A in the figure is the overall relationship between TRIM27 mRNA expression and OS of NSCLC patients, B is the 1-year OS of NSCLC patients, C is the 3-year OS of NSCLC patients, and D is the 5-year OS of NSCLC patients);

[0026] Figure 7 The relationship between TRIM27 mRNA expression level and first progression (FP) of NSCLC patients ( Figure 6 A in the figure is the overall relationship between TRIM27 mRNA expression and FP of NSCLC patients, B is the 1-year FP of NSCLC patients, C is the 3-year FP of NSCLC patients, and D is the 5-year FP of NSCLC patients);

[0027] Figure 8 The relationship between TRIM27 mRNA expression level and post-progression survival (PPS) of NSCLC patients ( Figure 6 A in the figure is the overall relationship between TRIM27 mRNA expression and PPS of NSCLC patients, B is the 1-year PPS of NSCLC patients, C is the 3-year PPS of NSCLC patients, and D is the 5-year PPS of NSCLC patients);

[0028] Fig. 9 In the GSE31210 dataset, high TRIM27 mRNA expression was associated with poor recurrence-free survival (RFS) in NSCLC patients;

[0029] Fig.10 In the GSE13213 and GSE14814 datasets, high TRIM27 mRNA expression was associated with poor OS in NSCLC patients ( Fig.10 A is the GSE13213 dataset, and B is the GSE14814 dataset);

[0030] Fig.11 TRIM27 promoter methylation status in normal lung tissue or primary tumor tissue of patients with LUAD or LUSC in the UALCAN database ( Fig.11 A is LUAD, B is LUSC);

[0031] Fig.12 The correlation between TRIM27 mRNA expression and promoter methylation in patients with LUAD or LUSC in LinkedOmics ( Fig.12 A is LUAD, B is LUSC);

[0032] Fig.13 Correlation between TRIM27 mRNA expression and genomic copy number changes in LUAD or LUSC patients in cBioPortal ( Fig.13 A is LUAD, B is LUSC);

[0033] Fig.14 Figure 2 Correlation between TRIM27 mRNA expression and genomic copy number changes in patients with LUAD (left) or LUSC (right) in the LinkedOmics database ( Fig.14 A is LUAD, B is LUSC);

[0034] Fig.15 This is the predicted substrate map of TRIM27 in the UbiBrowser database;

[0035] Fig.16 The results of real-time quantitative PCR detection of TRIM27 in HCC827 cells after TRIM27 knockout;

[0036] Fig.17 Western blot analysis of TRIM27 and TP53 protein levels in HCC827 and NCI-H460 cells when TRIM27 is deficient ( Fig.17 A is HCC827, B is NCI-H460);

[0037] Fig.18 Statistical analysis of TRIM27 and TP53 protein expression in HCC827 and NCI-H460 cells when TRIM27 is deficient ( Fig.18 A is HCC827, B is NCI-H460);

[0038] Fig.19 MTT quantification of NSCLC cells after TRIM27 loss ( Fig.19 A is HCC827, B is NCI-H460);

[0039] Fig. 20 The cell cycle distribution of NSCLC cells after TRIM27 knockout ( Fig. 20 A in the figure is a flow cytometry analysis diagram, B is a statistical analysis of the cycle distribution of HCC827, and C is a statistical analysis of the cycle distribution of NCI-H460);

[0040] Fig.21 Figure 2 shows the migration and invasion of NSCLC cells when TRIM27 is missing. Fig.21 A is a representative image of cell migration, B is a statistical analysis of cell migration of HCC827, C is a statistical analysis of cell migration of NCI-H460, D is a representative image of cell invasion, E is a statistical analysis of cell invasion of HCC827, C is a statistical analysis of cell invasion of NCI-H460);

[0041] Fig. 22 Representative images and statistical analysis of the tumor sphere-forming ability of NSCLC cells after TRIM27 loss ( Fig. 22 A in the figure is a representative image, B is the statistical analysis of HCC827, and C is the statistical analysis of NCI-H460);

[0042] Fig.23 Representative images and statistical analysis of CD44 expression on the surface of NSCLC cells in the absence of TRIM27 ( Fig.23 A in the figure is a representative image, B is the statistical analysis of HCC827, and C is the statistical analysis of NCI-H460);

[0043] Fig.24 Representative images and statistical analysis of CD44 and Epcam expression in NSCLC cells after TRIM27 depletion ( Fig.24 A in the figure is a representative image of HCC827, B is a representative image of NCI-H460, C is a statistical analysis of HCC827, and D is a statistical analysis of NCI-H460);

[0044] Fig.25 The interaction between TRIM27 and TP53 proteins in HEK293T cells transfected with Fig.25 A in the figure is co-immunoprecipitation analysis, and B is in vitro interaction experiment);

[0045] Fig.26 Effects of TRIM27 on TP53 protein expression and ubiquitination ( Fig.26A is a bar graph showing the effect of TRIM27 shRNA-mediated knockdown on TP53 protein expression before and after MG132 treatment, B is a statistical graph showing the effect of TRIM27 shRNA-mediated knockdown on TP53 protein expression before and after MG132 treatment, C is the effect of TRIM27 on the ubiquitination level of TP53 protein in HEK293T cells, D is a representative image of Western blotting analysis of TP53 protein expression in TRIM27-overexpressing HCC827 cells, and E is a statistical analysis of Western blotting analysis of TP53 protein expression in TRIM27-overexpressing HCC827 cells);

[0046] Fig. 27 Real-time quantitative PCR detection of TP53 mRNA in HCC827 cells after TP53 knockdown by three independent shRNAs;

[0047] Fig.28 Effect of TRIM27 knockdown on NSCLC cell survival ( Fig.28 A in the figure is the quantitative detection of TRIM27 and TP53 protein expression by western blot in NSCLC cells lacking TRIM27 or TP53, B is the statistical analysis of western blot in HCC827 cells, C is the statistical analysis of western blot in NCI-H460 cells, D is the MTT analysis of HCC827 cells, and E is the MTT analysis of NCI-H460 cells);

[0048] Fig.29 Representative images and statistical analysis of the sphere-forming ability of TRIM27 or TP53-deficient NSCLC cells ( Fig.29 A in the figure is a representative image, and B is a statistical analysis);

[0049] Fig.30 Representative images and statistical analysis of CD44 expression on the surface of NSCLC cells when TRIM27 or TP53 is missing ( Fig.29 A in the figure is a representative image, and B is a statistical analysis);

[0050] Fig.31 Representative images and statistical analysis of CD44 and Epcam expression in TRIM27 or TP53-deficient NSCLC cells ( Fig.31 A is a representative image, B is a statistical analysis of HCC827 cells, and C is a statistical analysis of NCI-H460 cells). DETAILED DESCRIPTION

[0051] The present invention provides a TRIM27 protein expression inhibitor, including a shRNA plasmid for knocking down TRIM27.

[0052] In the present invention, the functional sequences in the shRNA plasmid include the shTRIM27-1 sequence group, the shTRIM27-2 sequence group and the shTRIM27-3 sequence group.

[0053] In the present invention, the shTRIM27-1 sequence group includes shTRIM27-1-F and shTRIM27-1-R, the sequence of the shTRIM27-1-F is shown in SEQ ID NO.1, and the specific sequence is 5'-CCGGCCCGAGAGGTTCAATCTGTTTCTCGAGAAACAGATTGAACCTCTCGGGTTTTT-3'; the sequence of the shTRIM27-1-R is shown in SEQ ID NO.2, and the specific sequence is 5'-AATTAAAAACCCGAGAGGTTCAATCTGTTTCTCGAGAAACAGATTGAACCTCTCGGG-3'.

[0054] In the present invention, the shTRIM27-2 sequence group includes shTRIM27-2-F and shTRIM27-2-R. The sequence of the shTRIM27-2-F is shown in SEQ ID NO.3, specifically 5'-CCGGCAGCCTGATCCTCTCTGATAACTCGAGTTATCAGAGAGGATCAGGCTGTTTTT-3'; the sequence of the shTRIM27-2-R is shown in SEQ ID NO.4, specifically 5'-AATTAAAAACAGCCTGATCCTCTCTGATAACTCGAGTTATCAGAGAGGATCAGGCTG-3'.

[0055] In the present invention, the shTRIM27-3 sequence group includes shTRIM27-3-F and shTRIM27-3-R, the sequence of shTRIM27-3-F is shown in SEQ ID NO.5, and the specific sequence is 5'-CCGGCACCTCCAGATTTGCAAGAGACTCGAGTCTCTTGCAAATCTGGAGGTGTTTTT-3'; the sequence of shTRIM27-3-R is shown in SEQ ID NO.6, and the specific sequence is 5'-AATTAAAAACACCTCCAGATTTGCAAGAGACTCGAGTCTCTTGCAAATCTGGAGGTG-3'.

[0056] The present invention also provides the use of the TRIM27 protein expression inhibitor in the preparation of a drug for treating non-small cell lung cancer.

[0057] The present invention also provides the use of the TRIM27 protein expression inhibitor in the preparation of a drug for reducing the vitality of non-small cell lung cancer cells.

[0058] The present invention also provides the use of the TRIM27 protein expression inhibitor in the preparation of a drug for reducing the migration and invasion ability of non-small cell lung cancer cells.

[0059] The present invention also provides the use of the TRIM27 protein expression inhibitor in the preparation of a drug for reducing the stemness of non-small cell lung cancer cells.

[0060] The present invention also provides the use of TRIM27 protein in the preparation of a drug for regulating the stability of TP53 protein, which can promote the maintenance of the stability of TP53 protein by inhibiting the expression of TRIM27 protein.

[0061] The present invention also provides the use of TRIM27 protein in preparing a reagent for regulating the expression level of TP53 protein. In cells, the expression level of TP53 protein can be increased by inhibiting the expression of TRIM27 protein.

[0062] The present invention also provides a regulator for regulating TP53 protein stability and / or TP53 protein expression level, including the TRIM27 protein expression inhibitor.

[0063] The technical solutions provided by the present invention are described in detail below in conjunction with the embodiments, but they should not be construed as limiting the protection scope of the present invention.

[0064] Example 1 Effect of TRIM27 on the development and progression of NSCLC

[0065] (I) TRIM27 mRNA expression in NSCLC patients 1.

[0067] Since the expression pattern of TRIM27 mRNA in cancer has not been well studied, bioinformatics analysis was performed to investigate the relationship between TRIM27 mRNA and NSCLC patients by examining the transcriptome data of NSCLC patients in the TIMER, UALCAN, and TNMplot databases.

[0068] The original RNA-seq data of NSCLC patient tissues were derived from the TIMER (https: / / cistrome.shinyapps.io / timer / ), UALCAN (https: / / ualcan.path.uab.edu / ), and TNMplot (https: / / tnmplot.com / analysis / ) databases.

[0069] Analysis of transcriptomic data from the TIMER database showed that TRIM27 mRNA levels were enhanced in more than half of the tested cancer types, including LUAD and LUSC ( Figure 1 ); UALCAN database mining showed that TRIM27 mRNA expression was elevated in both NSCLC subtypes (e.g. Figure 2 ); the results of TNMplot database confirmed this observation (e.g. Figure 3 ); TRIM27 mRNA expression was upregulated in the invasive grade or stage of LUAD and LUSC (e.g. Figure 4 and Figure 5 ). Elevated TRIM27 mRNA expression in tumor samples was not consistently associated with TP53 mutation status, patient age, race, or sex. 2.

[0071] To examine the relationship between TRIM27 mRNA levels and the prognosis of NSCLC patients, the patient survival data were analyzed using the Kaplan-Meier plot database and the Gene Expression Omnibus dataset.

[0072] In Kaplan-Meier Plotter (http: / / www.kmplot.com / analysis / index.php?p=background), the "automatic selection of optimal cutoff" method was used to divide patients into TRIM27 high level group and TRIM27 low level group, and the Kaplan-Meier curves of OS, FP and PPS of lung cancer patients were drawn. In the R package survminerv.0.4.8, the optimal cutoff was automatically selected to divide patients from the Gene Expression Omnibus dataset (https: / / www.ncbi.nlm.nih.gov / geo / , accession numbers: GSE31210, GSE13213 and GSE14814) into TRIM27 high level group and TRIM27 low level group, and the Kaplan-Meier curves of RFS and OS of patients were drawn.

[0073] The results are as follows Figure 6-8 As shown in Figure 2, high levels of TRIM27 were associated with poor overall survival (OS), first progression (FP), and post-progression survival (PPS) in NSCLC patients. Similarly, in the GSE13213 dataset and the GSE14814 dataset, higher levels of TRIM27 were associated with poor recurrence-free survival (RFS) and OS (Figure 2). Fig. 9 and Fig.10 ).

[0074] In summary, it can be concluded that TRIM27 mRNA expression is elevated in NSCLC patients and is associated with poor survival.

[0075] (II) Analysis of TRIM27 mRNA expression, promoter methylation, and copy number changes

[0076] To further elucidate the mechanism by which TRIM27 mRNA levels were enhanced in NSCLC patients, the relationship between TRIM27 mRNA levels and promoter methylation was first investigated.

[0077] TRIM27 promoter methylation and copy number change data were downloaded from LinkedOmics (https: / / www.linkedomics.org / login.php) and UALCAN (https: / / ualcan.path.uab.edu / ) databases, respectively. The results showed that compared with normal tissues, TRIM27 promoter methylation was downregulated in primary NSCLC tumor samples (e.g. Fig.11 A significant inverse correlation between TRIM27 mRNA expression and promoter methylation was observed in UALCAN and LinkedOmics (e.g. Fig.12 ). Then, we examined whether there was a change in TRIM27 copy number in NSCIC patient samples by dividing the patients into four groups with different TRIM27 gene status. Through cbiopportal (https: / / www.cbioportal.org / ) and LinkedOmics, the expression of TRIM27 mRNA was positively correlated with the increase in its gene copy number (e.g. Fig.13 and Fig.14 The possible interacting proteins of TRIM27 in NSCLC patients were also analyzed using the UbiBrowser database (http: / / ubibrowser.bio-it.cn / ubibrowser / home / index). Multiple proteins including TP53 are candidate proteins that may interact with TRIM27 (e.g. Fig.15 ).

[0078] (III) Effect of TRIM27 on the viability, cell cycle, migration and invasion of NSCLC cells

[0079] Since the results of bioinformatics analysis suggested that TRIM27 may function as a tumor promoter in NSCLC, loss-of-function experiments were performed to determine the biological effects of TRIM27 on NSCLC cells.

[0080] HCC827 and NCI-H460 cells were purchased from Xiamen IMMOCELL Biotechnology Co., Ltd. (IMMOCELL, Xiamen, China) and cultured in RPMI-1640 medium (Thermo Fisher Scientific, 11875119) containing 10% fetal bovine serum (FBS, Thermo Fisher Scientific, 26140079). All cells were cultured in a 37°C, 5% CO2 incubator.

[0081] Design, synthesize shTRIM27-1, shTRIM27-2, and shTRIM27-3, perform functional verification, and select the two best shRNA targets. Use pLKO.1-TRC (purchased from Xiamen Antihera Biotechnology Co., Ltd.) to generate a plasmid encoding short hairpin RNA (shRNAs) of TRIM27, named shTRIM27. At the same time, set the pLKO.1-TRC empty vector as a control group (shNC). See Table 1 for specific sequence information.

[0082] Table 1 Sequence information

[0083]

[0084]

[0085] 1. Real-time quantitative PCR detection

[0086] HCC827 cells (1×10 6 ) were inoculated into 6-well plates and cultured overnight. 5 μg of the shTRIM27 plasmid obtained above was transfected into ( Transfection reagent, T101, Vazyme, Nanjing, China) was added to the non-small cell lung cancer cell line HCC827. After 48 h, TRIM27 in the cells was detected by real-time quantitative PCR. RNA was extracted using TRIzol reagent (Invitrogen, 15596026). The extracted RNA was reverse transcribed using ReverTra AceH RT Kit (Thermo Fisher Scientific, K1621). SYBR TM Real-time quantitative PCR was performed using Green PCR premix (Thermo Fisher Scientific, 4309155) and CFX Connect Detection System (Bio-Rad). 18S RNA was used as an internal control and 2 -ΔΔCtThe relative expression was calculated by the algorithm. The experiment was repeated 3 times independently. The primer information is shown in Table 2, the amplification system is shown in Table 3, and the amplification program is shown in Table 4.

[0087] Table 2 Sequence information

[0088] sequence name Sequence information (5'→3') Sequence number TP53-F CCTCAGCATCTTATCCGAGTGG SED ID NO.7 TP53-R TGGATGGTGGTACAGTCAGAGC SED ID NO.8 TRIM27-F AGCCTGATCGCTCAGCTAGAAG SED ID NO.9 TRIM27-R GGAGGTGTGATCCAAGGTTCAG SED ID NO.10 18S-F AGGCGCGCAAATTACCCAATCC SED ID NO.11 18S-R GCCTCCAATTGTTCCTCGTTAAG SED ID NO.12

[0089] Table 3 Real-time quantitative PCR amplification system

[0090]

[0091] Table 4 Real-time quantitative PCR amplification program

[0092]

[0093] The results are as follows Fig.16 As shown, in HCC827 cells after TRIM27 knockout, the shTRIM27-1 group and the shTRIM27-2 group showed strong knockdown efficiency at the mRNA level.

[0094] 2. Western Blot

[0095] HCC827 and NCI-H460 cells (1×10 6 ) were inoculated in 6-well plates and cultured overnight. The shTRIM27 plasmid obtained by the above design was transfected into non-small cell lung cancer cell lines HCC827 and NCI-H460. The protein immunoblotting of TRIM27 and TP53 protein levels in HCC827 and NCI-H460 cells when TRIM27 was missing was analyzed.

[0096] The cells were lysed using RIPA buffer (Beyotime, P0013B). The total protein concentration was quantified using a BCA kit (Thermo Fisher Scientific, 23225). The proteins were separated using SDS-PAGE and then transferred to a 0.45 μm polyvinylidene fluoride membrane. After blocking with 5% skim milk at 25°C for 1 hour, the membrane was incubated with TRIM27 antibody (Proteintech, catalog number: 12205-1-AP), flag antibody (Proteintech, catalog number: 20543-1-AP), HA antibody (Proteintech, catalog number: 51064-2-AP), ubiquitin antibody (Proteintech, catalog number: 10201-2-AP), β-tubulin antibody (Proteintech, Catalog number: 10201-2-AP), 10094-1-AP), His antibody (Proteintech, catalog number: 10001-0-AP), TP53 antibody (Abcam, catalog number: ab32049) or β-actin antibody (Proteintech, catalog number: 20536-1-AP) were incubated at 25°C for 2 hours, followed by incubation with horseradish peroxidase-conjugated goat anti-rabbit IgG (Proteintech, catalog number: SA00001-2). After detection with primary and secondary antibodies, signals were detected using a typical enhanced chemiluminescence kit (Thermo Fisher Scientific, Inc.), X-ray film (Beyotime, FF058) and a developing and fixing kit (Beyotime, P0019). The experiment was repeated three times independently.

[0097] The results are as follows Fig.17 and Fig.18 As shown, successful deletion of TRIM27 was verified at the protein level in HCC827 and NCI-H460 NSCLC cell lines, and the levels of TP53 were significantly enhanced in both cell lines when TRIM27 was knocked down.

[0098] 3. Cell Viability Assay

[0099] To evaluate the effect of TRIM27 on NSCLC cell survival, a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)-based viability assay was performed.

[0100] HCC827 and NCI-H460 cells (1×10 4 ) were inoculated into 96-well plates and cultured overnight. 0.2 μg of the shTRIM27 plasmid obtained above was transfected into ( Transfection reagent, T101, Vazyme, Nanjing, China) was added to the non-small cell lung cancer cell line HCC827. MTT reagent (Thermo Fisher Scientific, M6494) was added 0, 24, 48 or 72 h after transfection and incubated at 37 °C for 4 h. The cells were dissolved in dimethyl sulfoxide and the optical density at 490 nm was measured using a microplate reader (Bio-Rad). The experiment was repeated 3 times independently, with 2 replicates in each group. The results are shown in Fig.19 As shown, loss of TRIM27 resulted in decreased viability of NSCLC cells.

[0101] 4. Cell Cycle Assay

[0102] HCC827 and NCI-H460 cells (1×10 6 ) were inoculated in 6-well plates and cultured overnight. The shTRIM27 plasmid obtained by the above design was transfected into non-small cell lung cancer cell lines HCC827 and NCI-H460. After 48 hours of transfection, HCC827 and NCI-H460 cells were collected and stained with 7-aminoactinomycin D (7-AAD, Thermo Fisher Scientific). Fluorescence was captured using a NovoCyte flow cytometer. The experiment was repeated 3 times independently. The results are shown in Fig. 20 As shown, TRIM27 knockdown NSCLC cells were arrested in the G0 / G1 phase compared with the control group.

[0103] 5. Cell Migration and Invasion Assay

[0104] TRIM27 knockdown HCC827 and NCI-H460 cells (1×10 5 ) were resuspended in 100 μL serum-free medium and added to the upper chamber of a 24-well Transwell plate (Corning, 3422) with 8 μm pore size without (for migration assay) or with (for invasion assay) Matrigel, and 500 μL RPM-1640 containing 10% FBS was added to the lower chamber. After 2 days, the stained cells were imaged. The experiment was repeated 3 times independently.

[0105] The results are as follows Fig.21 As shown, knockdown of TRIM27 alleviated the migration and invasion abilities of NSCLC cells.

[0106] In summary, loss of TRIM27 alleviated the survival, migration, and invasion of NSCLC cells.

[0107] (IV) Effect of TRIM27 on stemness of NSCLC cells

[0108] Given that cancer stem cells are more resistant to chemotherapy and contribute greatly to cancer recurrence, we explored the effect of loss of TRIM27 on the stem cell properties of NSCLC cells.

[0109] 1. Tumor sphere formation assay

[0110] HCC827 and NCI-H460 cells (1×10 3 ) were seeded in wells of a 24-well plate and cultured in RPMI-1640 with 2% B27 (Gibco), 20 ng / mL epidermal growth factor (Gibco), 20 ng / mL basic fibroblast growth factor (Novoprotein, China), and 4 μg / mL insulin (Gibco). Images were collected after 2-3 weeks of tumor sphere culture. The experiment was repeated 3 times independently.

[0111] Tumor sphere formation experiments showed that Fig. 22 ), knockdown of TRIM27 reduced the tumor sphere-forming ability of NSCLC cells.

[0112] 2. Detection of stemness markers

[0113] HCC827 and NCI-H460 cells (1×10 6 ) were inoculated in 6-well plates and cultured overnight. The shTRIM27 plasmid obtained by the above design was transfected into non-small cell lung cancer cell lines HCC827 and NCI-H460. After 48 hours of transfection, HCC827 and NCI-H460 cells were collected. Incubated with fluorescein isothiocyanate-coupled CD44 antibody (SinoBiological, catalog number: 12211-MM02-F). Then, fluorescence was captured using a NovoCyte flow cytometer. Alternatively, by protein immunoblotting experiments, the protein levels of intracellular CD44 and Epcam were detected using CD44 antibodies (Proteintech, catalog number: 15675-1-AP) and epithelial cell adhesion molecule (Epcam) antibodies (Proteintech, catalog number: 21050-1-AP). The experiment was repeated 3 times independently.

[0114] The results showed that in the absence of TRIM27, the level of stemness marker CD44 on the cell surface was downregulated (e.g. Fig.23 In addition, Western blotting results showed that NSCLC cells lacking TRIM27 showed reduced protein levels of stem cell markers CD44 and Epcam (e.g. Fig.24 ). These results suggest that the stemness of NSCLC cells is reduced when TRIM27 is lost.

[0115] Example 2 Regulatory influence of TRIM27 and TP53 protein stability and expression level

[0116] (I) TRIM27 affects the stability and ubiquitination of TP53 protein

[0117] The plasmid encoding His-ubiquitin (His-Ub) was obtained from Xiamen Anti-Hela Biotechnology Co., Ltd. The plasmid encoding TRIM27 or TP53 was constructed using pLV-EF1a-HA-IRES or pLV-EF1a-Flag-IRES backbone (purchased from Xiamen Anti-Hela Biotechnology Co., Ltd.), named HA-TRIM27 and Flag-TP53, respectively. The specific sequences are shown in Table 5.

[0118] Table 5 Sequence information

[0119]

[0120] 1. Verify the interaction between TRIM27 and TP53

[0121] Immunoprecipitation experiment: HCC827 cells were seeded in 6-well plates (2×10 6 cells / well) overnight. HCC827 cells were transfected with plasmids encoding HA-TRIM27 and Flag-TP53 separately or co-transfected. 24 hours after transfection, the cells were harvested and lysed with cell lysis buffer supplemented with protease inhibitors. The cell lysate was then incubated with magnetic beads coupled to HA (Beyotime, catalog number: P2121) or flag (Beyotime, catalog number: P2115) antibodies at 4°C overnight. The immunoprecipitate was washed with cell lysis buffer and then detected by protein immunoblotting. The experiment was repeated 3 times independently.

[0122] GST pull-down assay: His-TRIM27, GST-TP53, and GST proteins were obtained from Xiamen Antihera Biotechnology Co., Ltd. 20 mg of purified GST-TP53 or GST protein was incubated with 20 mg of His-TRIM27 protein, and the protein complex was precipitated with glutathione-sepharose 4B and finally detected by western blotting.

[0123] The results of co-immunoprecipitation experiments showed that there was an interaction between TP53 and TRIM27, and GST pull-down assays using purified proteins confirmed their direct binding (e.g. Fig.25 ). 2.

[0125] shTRIM27 and its control plasmid were transfected into human lung cancer cell line HCC827 cells. After 42 hours, the culture medium was replaced with 10 μM MG132 and cultured for another 6 hours. The cells were then collected, total protein was extracted, and the protein level of endogenous TP53 was detected by western blotting to explore the degradation of TP53.

[0126] Ubiquitination regulation: HCC827 cells were co-transfected with shTRIM27 and its control plasmids, Flag-TP53, and His-Ub, respectively. After 42 hours, the culture medium was replaced with 10 μM MG132 and cultured for another 6 hours. The cells were then collected, total protein was extracted, and the ubiquitination of TP53 protein was detected using immunoprecipitation assay.

[0127] Half-life detection: HCC827 cells were co-transfected with shTRIM2 and its control plasmids and FLAG-TP53, respectively. After 24 hours, the cells were replaced with 50 μg / mL cycloheximide (CHX) for 0, 30, 60, 120, and 240 min, and the cells were collected, total protein was extracted, and protein changes of TP53 and TRIM27 were detected by western blotting.

[0128] HCC827 cells were treated with MG132 proteasome inhibitor to study the degradation pathway of TP53 protein. Fig.26 ): Regardless of the presence or absence of MG132, the reduction of TRIM27 enhances the expression of TP53; when TRIM27 is knocked out, the ubiquitination level of TP53 is weakened; ectopic expression of TRIM27 destroys the stability of TP53 protein. Therefore, it can be concluded that TRIM27 interacts with TP53 protein and ubiquitinates TP53 protein, and TP53 protein is a substrate for TRIM27 ubiquitination and degradation.

[0129] (II) TRIM27 affects the expression level of TP53 protein

[0130] The pLKO.1-TRC vector was used to construct plasmids encoding short hairpin RNA (shRNAs) of TP53, which were named shTP53. At the same time, the pLKO.1-TRC empty vector was set as a control group (shNC). The specific sequence information is shown in Table 6.

[0131] Table 6 Sequence information

[0132]

[0133] We further investigated whether the inhibition of NSCLC progression by TRIM27 was dependent on TP53. Real-time quantitative PCR of TP53 mRNA in HCC827 cells after knocking down TP53 by three independent shRNAs was performed, and the results showed that the most effective shRNA against TP53 was shTP53-1. Fig. 27 In NSCLC cells lacking TRIM27 or TP53, protein immunoblotting was used to quantitatively detect the expression of TRIM27 and TP53 proteins, and MTT was used to analyze the viability of NSCLC cells after TRIM27 or TP53 knockout. The results showed that (e.g. Fig.28 ): When TP53 is missing, the inhibition of NSCLC cell survival by TRIM27 knockdown is alleviated.

[0134] (III) Relationship between TRIM27, TP53 proteins and NSCLC cell stemness

[0135] The tumor sphere formation ability, CD44 expression and EpCAM expression of TRIM27 or TP53-deficient NSCLC cells were measured. Figure 29-31 In the absence of TRIM27, the tumor sphere formation and the inhibition of CD44 and EpCAM expression promoted by TP53 deficiency were also weakened. Therefore, it can be concluded that knocking down TRIM27 can increase TP53 protein levels, thereby inhibiting the proliferation and stemness of non-small cell lung cancer cells.

[0136] In summary, it can be seen that knocking down TRIM27 through the technical solution of the present invention can reduce the survival, migration, invasion and stemness of NSCLC cells, and can also weaken the ubiquitination level of TP53, enhance the stability and expression level of TP53 protein, and thus inhibit the proliferation and stemness of non-small cell lung cancer cells.

[0137] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.

Claims

1. A TRIM27 protein expression inhibitor, It is characterized in that Included are shRNA plasmids for knocking down TRIM27.

2. The expression inhibitor according to claim 1, It is characterized in that The functional sequences in the shRNA plasmid include shTRIM27-1 sequence group, shTRIM27-2 sequence group and shTRIM27-3 sequence group; The shTRIM27-1 sequence group includes shTRIM27-1-F and shTRIM27-1-R, the sequence of shTRIM27-1-F is shown in SEQ ID NO.1, and the sequence of shTRIM27-1-R is shown in SEQ ID NO.2; The shTRIM27-2 sequence group includes shTRIM27-2-F and shTRIM27-2-R, the sequence of shTRIM27-2-F is shown in SEQ ID NO.3, and the sequence of shTRIM27-2-R is shown in SEQ ID NO.4; The shTRIM27-3 sequence group includes shTRIM27-3-F and shTRIM27-3-R, the sequence of shTRIM27-3-F is shown in SEQ ID NO.5, and the sequence of shTRIM27-3-R is shown in SEQ ID NO.

6.

3. Use of the TRIM27 protein expression inhibitor according to claim 1 or 2 in the preparation of a drug for treating non-small cell lung cancer.

4. Use of the TRIM27 protein expression inhibitor according to claim 1 or 2 in the preparation of a drug for reducing the viability of non-small cell lung cancer cells.

5. Use of the TRIM27 protein expression inhibitor according to claim 1 or 2 in the preparation of a drug for reducing the migration and invasion ability of non-small cell lung cancer cells.

6. Use of the TRIM27 protein expression inhibitor according to claim 1 or 2 in the preparation of a drug for reducing the stemness of non-small cell lung cancer cells.

7. Application of TRIM27 protein in the preparation of drugs for regulating the stability of TP53 protein, It is characterized in that Inhibiting TRIM27 protein expression can promote the maintenance of TP53 protein stability.

8. Application of TRIM27 protein in the preparation of reagents for regulating TP53 protein expression levels, It is characterized in that In cells, inhibiting TRIM27 protein expression can increase TP53 protein expression levels.

9. A regulator for regulating TP53 protein stability and / or TP53 protein expression level, It is characterized in that Comprising the TRIM27 protein expression inhibitor according to claim 1 or 2.

Citation Information

Cited By

  • Application of TRIM27 gene as target spot in screening medicine for treating mitochondrial autophagy abnormality related diseases

    CN120703372A